Reata Pharmaceuticals announced plans to initiate a study using the drug bardoxolone methyl in the treatment of chronic kidney disease caused by Alport Syndrome. The clinical trial (CARDINAL) will study how bardoxolone methyl affects the chronic inflammation and decline in kidney function that are key features of Alport Syndrome.
Regulus Therapeutics is pleased to announce the initiation of the HERA study, an interventional clinical study in Alport syndrome patients. The purpose of this research study is to evaluate the safety and effectiveness of an investigational drug (an anti-microRNA 21 called RG-012) compared to placebo as a treatment for patients with Alport syndrome.
Over the past nine years, ASF has successfully created a landscape that encourages industry, academia and the government to invest in studying Alport Syndrome. The result can be seen in the increased number of potential therapies “in the pipeline” to treat Alport Syndrome.
ASF is taking steps to better incorporate the patient perspective into our research goals. To better understand the daily and long-term impact that Alport Syndrome has on patients and the main concerns patients have about the disease and its progression, we have created a survey.
This is an exciting and busy time at ASF as many steps are being taken towards conquering Alport Syndrome. While we are grateful for the lifesaving treatments of dialysis and transplantation, ASF is the only national organization dedicated entirely to finding treatments aimed specifically at Alport Syndrome.
Celina LaBrec-Salmons was the first person to register for the first-ever Alport Syndrome Virtual Walk, which will be held on June 18. This is a national event to raise funds and awareness by encouraging people to participate in their own communities.
My first six weeks as ASF’s first Executive Director have been quite exciting. During that time, I have come to greatly appreciate the importance of raising funds and awareness dedicated specifically to conquering Alport Syndrome.